Formulation And Evaluation of Floating Drug Delivery System of Benazepril

The research focuses on developing a floating drug delivery system for Benazepril, aimed at enhancing its absorption and prolonging gastric residence time, thereby improving bioavailability. Floating drug delivery systems (FDDS) maintain buoyancy in gastric fluids, allowing for extended action and reduced dosing frequency. The formulation of floating tablets utilized Carbopol 940, Guar gum, and HPMC K100M as polymers through direct compression, resulting in nine Formulations (F1-F9). Preformulation parameters adhered to pharmacopoeial standards, and FTIR studies confirmed no incompatibility between the drug and polymers. Post-compression evaluations included weight variation, hardness, friability, thickness, drug content, in vitro buoyancy, and dissolution studies. The micromeritic properties were satisfactory, with formulation F9 exhibiting optimal in vitro buoyancy lag time and floating duration. This Formulation F9 achieved a 98.3% drug release over 12 hours, demonstrating superior control over the release rate compared to others. Stability data indicated no significant changes in parameters over time. Therefore, Formulation F9 is recognized as stable and effective in significantly increasing gastric residence time for Benazepril, thus enhancing its bioavailability.